Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 2/20 | 0.34 |
| ▸ | CTSL | P07711 | 2/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | CTSS | P25774 | 1/20 | 0.34 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.33 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10164748 | 0.89 | MAPK8 (0.41) | MAPK8SMN1; SMN2NPC1RAB9AP2RX7 | |
| SCHEMBL247704 | 0.84 | HDAC3 (0.34) | NPC1P2RX7ALDH1A1CTSLRXFP1 | |
| SCHEMBL10164591 | 0.82 | MAPK8 (0.36) | MAPK8SMN1; SMN2NPC1RAB9AP2RX7 | |
| SCHEMBL10164756 | 0.80 | KMT2A (0.42) | P2RX7ALDH1A1KMT2A | |
| SCHEMBL6764658 | 0.77 | MEN1 (0.42) | NPC1RAB9AP2RX7ALDH1A1TP53 | |
| SCHEMBL11888076 | 0.76 | MAPK8 (0.40) | MAPK8SMN1; SMN2NPC1RAB9AP2RX7 | |
| SCHEMBL6767098 | 0.75 | MEN1 (0.49) | NPC1RAB9AP2RX7ALDH1A1CTSL | |
| SCHEMBL8862910 | 0.74 | RXFP1 (0.45) | NPC1RAB9AALDH1A1RXFP1KMT2A | |
| SCHEMBL13884156 | 0.73 | MAPK8 (0.39) | MAPK8SMN1; SMN2NPC1RAB9AP2RX7 | |
| SCHEMBL8862680 | 0.73 | RXFP1 (0.47) | NPC1ALDH1A1RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2197844-B1 | SPIROHETEROCYCLIC PYRROLIDINE DIONE DERIVATIVES USEFUL AS PESTICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2012-07-25 | — | — | EP | disclosed |
| US-20120035201-A1 | SPIROHETEROCYCLIC PYRROLIDINE DIONE DERIVATIVES USED AS PESTICIDES | SYNGENTA CROP PROTECTION LLC (US) | 2012-02-09 | — | — | US | disclosed |
| US-20100311777-A1 | SPIROHETEROCYCLIC PYRROLIDINE DIONE DERIVATIVES USEFUL AS PESTICIDES | SYNGENTA CROP PROTECTION, INC. (US) | 2010-12-09 | — | — | US | disclosed |
| US-20100311777-A1 | SPIROHETEROCYCLIC PYRROLIDINE DIONE DERIVATIVES USEFUL AS PESTICIDES | SYNGENTA CROP PROTECTION, INC. (US) | 2010-12-09 | — | — | US | disclosed |
| WO-2010115780-A1 | SPIROHETEROCYCLIC PYRROLIDINE DIONE DERIVATIVES USED AS PESTICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2010-10-14 | — | — | WO | disclosed |
| WO-2009049851-A1 | SPIROHETEROCYCLIC PYRROLIDINE DIONE DERIVATIVES USEFUL AS PESTICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2009-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311777-A1 | SPIROHETEROCYCLIC PYRROLIDINE DIONE DERIVATIVES USEFUL AS PESTICIDES | DDT, PKD2, PKD1 | MAPK8 3963/4885SMN1; SMN2 3146/4885NPC1 3498/4885 |
| US-20120035201-A1 | SPIROHETEROCYCLIC PYRROLIDINE DIONE DERIVATIVES USED AS PESTICIDES | DDT, PKD2, PKD1 | MAPK8 4173/4885SMN1; SMN2 2581/4885NPC1 2090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.